Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

被引：0

作者：

D A Reardon

A Desjardins

J J Vredenburgh

S Gururangan

J H Sampson

S Sathornsumetee

R E McLendon

J E Herndon

J E Marcello

J Norfleet

A H Friedman

D D Bigner

H S Friedman

机构：

[1] The Preston Robert Tisch Brain Tumor Center,Department of Surgery

[2] Duke University Medical Center,Department of Pediatrics

[3] The Preston Robert Tisch Brain Tumor Center,Department of Medicine

[4] Duke University Medical Center,Department of Pathology

[5] The Preston Robert Tisch Brain Tumor Center,undefined

[6] Duke University Medical Center,undefined

[7] The Preston Robert Tisch Brain Tumor Center,undefined

[8] Duke University Medical Center,undefined

[9] Cancer Center Biostatistics,undefined

[10] The Preston Robert Tisch Brain Tumor Center,undefined

[11] Duke University Medical Center,undefined

来源：

British Journal of Cancer | 2009年 / 101卷

关键词：

malignant glioma; glioblastoma; angiogenesis; bevacizumab; vascular endothelial growth factor; metronomic chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1986 / 1994

页数：8

共 50 条

[1] Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
Reardon, D. A.
Desjardins, A.
Vredenburgh, J. J.
Gururangan, S.
Sampson, J. H.
Sathornsumetee, S.
McLendon, R. E.
Herndon, J. E., II
Marcello, J. E.
Norfleet, J.
Friedman, A. H.
Bigner, D. D.
Friedman, H. S.
BRITISH JOURNAL OF CANCER, 2009, 101 (12) : 1986 - 1994
[2] A PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS
Desjardins, Annick
Vredenburgh, James J.
Gururangan, Sridharan
Peters, Katherine B.
Friedman, Allan H.
Friedman, Henry
Reardon, David A.
NEURO-ONCOLOGY, 2009, 11 (05) : 633 - 633
[3] Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma
Rich, J. N.
Desjardins, A.
Sathornsumetee, S.
Vredenburgh, J. J.
Quinn, J. A.
Gururangan, S.
Friedman, A. H.
Friedman, H. S.
Reardon, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
Reardon, D.
Desjardins, A.
Vredenburgh, J. J.
Gururangan, S.
Peters, K. B.
Norfleet, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[5] PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS
Reardon, David A.
Desjardins, Annick
Vredenburgh, James J.
Gururangan, Sridharan
Peters, Katherine B.
Norfleet, Julie A.
Friedman, Allan H.
Friedman, Henry S.
NEURO-ONCOLOGY, 2009, 11 (06) : 905 - 905
[6] SAFETY AND EFFICACY OF BEVACIZUMAB AND METRONOMIC, ORAL ETOPOSIDE FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
Reardon, David
Desjardins, Annick
Vredenburgh, James
Rich, Jeremy
Gururangan, Sridharan
Sathornsumetee, Sith
Friedman, Allan
Friedman, Henry
NEURO-ONCOLOGY, 2008, 10 (05) : 839 - 839
[7] A PHASE I/II STUDY OF VORINOSTAT PLUS DAILY TEMOZOLOMIDE AND BEVACIZUMAB IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
Reardon, David A.
Vredenburgh, James J.
Desjardins, Annick
Janney, Dorothea E.
Peters, Katherine
Sampson, John
Gururangan, Sri
Friedman, Henry S.
NEURO-ONCOLOGY, 2010, 12 : 73 - 73
[8] Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study
Ashby, LS
Shapiro, WR
JOURNAL OF NEURO-ONCOLOGY, 2001, 51 (01) : 67 - 86
[9] Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: A phase II study
Ashby L.S.
Shapiro W.R.
Journal of Neuro-Oncology, 2001, 51 (1) : 67 - 86
[10] CARBOPLATIN AND ETOPOSIDE CHEMOTHERAPY REGIMEN FOR RECURRENT MALIGNANT GLIOMA - A PHASE-II STUDY
JEREMIC, B
GRUJICIC, D
JEVREMOVIC, S
STANISAVLJEVIC, B
MILOJEVIC, L
DJURIC, L
MIJATOVIC, L
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1074 - 1077

← 1 2 3 4 5 →